Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Evaluation of annexin A5 as a biomarker for Alzheimer's disease and dementia with lewy bodies.

Sohma H, Imai S, Takei N, Honda H, Matsumoto K, Utsumi K, Matsuki K, Hashimoto E, Saito T, Kokai Y.

Front Aging Neurosci. 2013 Apr 5;5:15. doi: 10.3389/fnagi.2013.00015. eCollection 2013.

2.

Apolipoprotein E4 frequencies in a Japanese population with Alzheimer's disease and dementia with Lewy bodies.

Kobayashi S, Tateno M, Park TW, Utsumi K, Sohma H, Ito YM, Kokai Y, Saito T.

PLoS One. 2011 Apr 28;6(4):e18569. doi: 10.1371/journal.pone.0018569.

3.

Apolipoprotein E ε2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort.

Berge G, Sando SB, Rongve A, Aarsland D, White LR.

J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1227-31. doi: 10.1136/jnnp-2013-307228. Epub 2014 Mar 17.

4.

Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.

Bousiges O, Cretin B, Lavaux T, Philippi N, Jung B, Hezard S, Heitz C, Demuynck C, Gabel A, Martin-Hunyadi C, Blanc F.

J Alzheimers Dis. 2016;51(4):1069-83. doi: 10.3233/JAD-150731.

PMID:
26923009
5.
6.

Investigation of annexin A5 as a biomarker for Alzheimer's disease using neuronal cell culture and mouse model.

Yamaguchi M, Kokai Y, Imai S, Utsumi K, Matsumoto K, Honda H, Mizue Y, Momma M, Maeda T, Toyomasu S, Ito YM, Kobayashi S, Hashimoto E, Saito T, Sohma H.

J Neurosci Res. 2010 Sep;88(12):2682-92. doi: 10.1002/jnr.22427.

PMID:
20648654
7.

CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.

Luo X, Hou L, Shi H, Zhong X, Zhang Y, Zheng D, Tan Y, Hu G, Mu N, Chan J, Chen X, Fang Y, Wu F, He H, Ning Y.

J Neurochem. 2013 Dec;127(5):681-90. doi: 10.1111/jnc.12331. Epub 2013 Jun 26.

8.

[Apolipoprotein E4 in dementia with Lewy bodies].

Carrillo García F, Gil Néciga E, Alberca R, García-Solís D, Millán J, Rodríguez Uranga JJ, Franco E, Mir P, Suárez A, García R, Serrano-Pozo A, Pérez-Díaz H, Polo J.

Neurologia. 2008 Apr;23(3):152-6. Spanish.

PMID:
18370334
9.

APOE-ε4 associates with hippocampal volume, learning, and memory across the spectrum of Alzheimer's disease and dementia with Lewy bodies.

Saeed U, Mirza SS, MacIntosh BJ, Herrmann N, Keith J, Ramirez J, Nestor SM, Yu Q, Knight J, Swardfager W, Potkin SG, Rogaeva E, St George-Hyslop P, Black SE, Masellis M.

Alzheimers Dement. 2018 Sep;14(9):1137-1147. doi: 10.1016/j.jalz.2018.04.005. Epub 2018 May 18.

PMID:
29782824
10.

CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.

Aerts MB, Esselink RA, Claassen JA, Abdo WF, Bloem BR, Verbeek MM.

J Alzheimers Dis. 2011;27(2):377-84. doi: 10.3233/JAD-2011-110482.

PMID:
21841257
11.

Olfactory function and neuropsychological profile to differentiate dementia with Lewy bodies from Alzheimer's disease in patients with mild cognitive impairment: A 5-year follow-up study.

Yoon JH, Kim M, Moon SY, Yong SW, Hong JM.

J Neurol Sci. 2015 Aug 15;355(1-2):174-9. doi: 10.1016/j.jns.2015.06.013. Epub 2015 Jun 10.

PMID:
26076880
12.

Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.

Ishiki A, Kamada M, Kawamura Y, Terao C, Shimoda F, Tomita N, Arai H, Furukawa K.

J Neurochem. 2016 Jan;136(2):258-61. doi: 10.1111/jnc.13399. Epub 2015 Nov 11.

13.

CYP2D6 is associated with Parkinson's disease but not with dementia with Lewy Bodies or Alzheimer's disease.

Atkinson A, Singleton AB, Steward A, Ince PG, Perry RH, McKeith IG, Fairbairn AF, Edwardson JA, Daly AK, Morris CM.

Pharmacogenetics. 1999 Feb;9(1):31-5.

PMID:
10208640
14.

[Neuropsychiatric features in Dementia with Lewy bodies and Alzheimer's disease].

Hirono N, Mori E, Imamura T, Shimomura T, Hashimoto M.

No To Shinkei. 1998 Jan;50(1):45-9. Japanese.

PMID:
9493198
15.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
16.

Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies.

Slaets S, Le Bastard N, Theuns J, Sleegers K, Verstraeten A, De Leenheir E, Luyckx J, Martin JJ, Van Broeckhoven C, Engelborghs S.

J Alzheimers Dis. 2013;35(1):137-46. doi: 10.3233/JAD-122176.

PMID:
23364139
17.

EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up.

Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M.

Brain. 2008 Mar;131(Pt 3):690-705. doi: 10.1093/brain/awm322. Epub 2008 Jan 17.

PMID:
18202105
18.

Dementia with Lewy bodies is associated with higher scores on the Geriatric Depression Scale than is Alzheimer's disease.

Yamane Y, Sakai K, Maeda K.

Psychogeriatrics. 2011 Sep;11(3):157-65. doi: 10.1111/j.1479-8301.2011.00368.x.

19.

1H-proton magnetic resonance spectroscopy differentiates dementia with Lewy bodies from Alzheimer's disease.

Zhong X, Shi H, Shen Z, Hou L, Luo X, Chen X, Liu S, Zhang Y, Zheng D, Tan Y, Huang G, Fang Y, Zhang H, Mu N, Chen J, Wu R, Ning Y.

J Alzheimers Dis. 2014;40(4):953-66. doi: 10.3233/JAD-131517.

PMID:
24531156
20.

Dose dependent effect of APOE epsilon4 on behavioral symptoms in frontal lobe dementia.

Engelborghs S, Dermaut B, Mariën P, Symons A, Vloeberghs E, Maertens K, Somers N, Goeman J, Rademakers R, Van den Broeck M, Pickut B, Cruts M, Van Broeckhoven C, De Deyn PP.

Neurobiol Aging. 2006 Feb;27(2):285-92.

PMID:
16399213

Supplemental Content

Support Center